InsiderSignalSign in

← Insider buys

PLSE

Pulse Biosciences, Inc. · Healthcare

Insiders bought $13.5M of Pulse Biosciences, Inc. in the last 12 months

3 insiders bought on 3 days.

$13.5MBought, 12 mo

$2.9MSold, 12 mo

$3.8BMarket cap

PLSE over the last year

Insider buy filed (3 days)

Largest buyers, last 12 months

PLSE after insider buys

3 months after each buy, from the first price a copier could get.

+11.4%Average

+3.3 ptsVs S&P 500

9 of 16Higher

16 buys since 2017 with 3 months of prices.

Every filing

47 insider filings since 2017, newest first

Liane Rae Teplitsky · Chief Operating Officer

$100K+97.8%Sep 2

Liane Rae Teplitsky · Chief Operating Officer

Paul A Laviolette · CEO

Robert W Duggan · Director and 10% owner

$13.0M+1.0%May 11

Kevin Patrick Danahy · Chief Commercial Officer

$118K−10.0%Feb 23

Kevin Patrick Danahy · Chief Commercial Officer

$1.4M−58.0%Feb 17

Kevin Patrick Danahy · Chief Commercial Officer

$1.4M−58.0%Feb 11

Robert W Duggan · Director and 10% owner

Robert W Duggan · Director and 10% owner

Robert W Duggan · Director and 10% owner

Robert W Duggan · Director and 10% owner

Burke Thomas Barrett · President and CEO

Robert W Duggan · Director and 10% owner

Robert W Duggan · Director and 10% owner

Robert W Duggan · Director and 10% owner

Robert W Duggan · Director and 10% owner

Robert W Duggan · Director and 10% owner

Robert W Duggan · Director and 10% owner

Robert W Duggan · Director and 10% owner

Robert W Duggan · Director and 10% owner

Robert W Duggan · Director and 10% owner

Robert W Duggan · Director and 10% owner

$2.0M+1.0%Dec 1

Robert W Duggan · Director and 10% owner

$65.2M+48.0%May 10

Robert W Duggan · Director and 10% owner

$50.0M+25.0%Jul 2

Robert W Duggan · Director and 10% owner

Maky Zanganeh · Director

Robert W Duggan · Director and 10% owner

Maky Zanganeh · Director

$92K+1.0%Dec 13

Robert W Duggan · 10% owner

Robert W Duggan · 10% owner

$30.0M+52.0%Sep 26

Maky Zanganeh · Director

$398K+8.0%Sep 18

Mitchell E. Levinson · Director

$47K−431.0%Sep 18

Robert W Duggan · 10% owner

$5.9M+12.0%Sep 18

Maky Zanganeh · Director

$690K+8.0%Aug 4

Robert W Duggan · 10% owner

$6.4M+9.0%Aug 3

Robert W Duggan · 10% owner

$2.3M+3.0%May 24

Thierry B. Thaure · Director

$244K−100.0%May 12

Maky Zanganeh · Director

$1.1M+17.0%May 11

Robert W Duggan · 10% owner

$913K+1.0%May 11

Robert J. Greenberg · Director

$528K−100.0%May 10

Thierry B. Thaure · Director

$337K−100.0%May 10

Robert W Duggan · 10% owner

$2.0M+3.0%May 2

Robert W Duggan · 10% owner

$877K+1.0%Apr 27

Robert W Duggan · 10% owner

$7.8M+12.0%Apr 19

Robert W Duggan · 10% owner

$3.8M+8.0%Apr 10

Robert W Duggan · 10% owner

$4.8M+9.0%Mar 20

Maky Zanganeh · Director

$426K+6.0%Mar 20

About Pulse Biosciences, Inc.

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.